Shares of Isoray, Inc. (NYSEAMERICAN:ISR) have been given an average recommendation of “Buy” by the six ratings firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $1.84.
Several analysts recently weighed in on the stock. Zacks Investment Research raised shares of Isoray from a “sell” rating to a “hold” rating in a report on Thursday, July 15th. Northland Securities initiated coverage on shares of Isoray in a report on Tuesday, September 14th. They set an “outperform” rating and a $1.25 price objective on the stock.
Several large investors have recently added to or reduced their stakes in ISR. Renaissance Technologies LLC raised its stake in shares of Isoray by 141.8% during the 1st quarter. Renaissance Technologies LLC now owns 3,260,228 shares of the healthcare company’s stock worth $3,554,000 after buying an additional 1,911,696 shares during the last quarter. BlackRock Inc. raised its stake in Isoray by 163.1% in the 1st quarter. BlackRock Inc. now owns 3,040,560 shares of the healthcare company’s stock valued at $3,315,000 after purchasing an additional 1,884,898 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Isoray by 204.0% during the 1st quarter. Geode Capital Management LLC now owns 984,227 shares of the healthcare company’s stock valued at $1,072,000 after acquiring an additional 660,491 shares during the last quarter. State Street Corp increased its stake in shares of Isoray by 4,807.3% during the 2nd quarter. State Street Corp now owns 519,042 shares of the healthcare company’s stock valued at $414,000 after acquiring an additional 508,465 shares during the last quarter. Finally, Bard Associates Inc. grew its holdings in shares of Isoray by 40.3% during the 2nd quarter. Bard Associates Inc. now owns 537,400 shares of the healthcare company’s stock worth $429,000 after purchasing an additional 154,400 shares during the period. 12.46% of the stock is owned by institutional investors and hedge funds.
Isoray (NYSEAMERICAN:ISR) last posted its quarterly earnings data on Monday, September 20th. The healthcare company reported ($0.01) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.01). Isoray had a negative net margin of 36.52% and a negative return on equity of 15.33%. During the same period last year, the business earned ($0.02) earnings per share. As a group, equities analysts anticipate that Isoray will post -0.03 EPS for the current year.
IsoRay, Inc is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors.
Further Reading: Mutual funds are not immune from market timing
Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with MarketBeat.com's FREE daily email newsletter.